Shocking Discovery: Kids Who Are Too Thin Might Ditch Their ADHD Meds Sooner – And It Could Change How We Treat Them Forever
Picture this: a young child battling the chaos of ADHD, where focus feels like chasing shadows and impulses take over like wild horses. Finally, they start a medication that promises calm and control – methylphenidate, the key ingredient in popular drugs like Concerta, Ritalin, or Medikinet. But what if their body weight plays a sneaky role in whether they stick with it? A groundbreaking study from the University of Gothenburg uncovers a troubling pattern: underweight kids are far more likely to quit their ADHD meds within the first year. This isn't just a statistic; it's a wake-up call for parents, doctors, and anyone involved in childhood health. Dive in with me as we unpack what this means, why it happens, and how we might fix it. But here's where it gets controversial – are we dosing ADHD meds fairly, or are subtle biases creeping in based on weight, gender, and age?
First off, let's break down ADHD and methylphenidate in simple terms, especially for beginners. ADHD, or Attention Deficit Hyperactivity Disorder, is a brain-based condition that can make it tough for kids (and adults) to pay attention, control impulses, or stay still. Think of it like a car's engine revving too high or too low – methylphenidate acts as a gentle tuner, helping the brain's neurotransmitters (those chemical messengers) regulate focus and impulse control. It's the go-to pharmacological treatment, available as tablets or capsules, and it's approved for children starting from age 6, as well as grown-ups. But like any medicine, getting the dose just right is crucial – too little might not help, and too much could cause side effects like jitteriness or appetite changes.
Now, onto the study, published in the journal Pediatric Drugs. Researchers analyzed data from 1,741 children and teens who began methylphenidate treatment. They tracked details like gender, age, body mass index (BMI – a simple measure of weight relative to height), and initial medication doses. For a subset of 612 kids, they followed up 6-12 months later, checking prescription changes and BMI updates. This real-world look at dosing practices revealed some eye-opening disparities tied to body weight.
And this is the part most people miss – the dosage differences weren't straightforward. On the surface, kids with overweight or obesity often got slightly higher absolute doses on their first prescription. But when the researchers adjusted for weight – calculating dose per kilogram of body mass – a different story emerged. Overweight and obese children actually received lower weight-adjusted doses. Flip that around for underweight kids: their weight-adjusted doses were higher than average. Imagine a tiny 8-year-old weighing 40 pounds and a heavier teen at 150 pounds – if they both get the same absolute dose, the smaller child gets a bigger "punch" per pound of body weight, which could explain why underweight kids might experience stronger effects or side effects.
Fast-forward to follow-up prescriptions, and the trends continued. Absolute dose increases were biggest for kids with obesity and smallest for those who were underweight. Plus, gender and age threw in their own twists: girls ended up with higher doses (both absolute and adjusted for weight) than boys, while kids over 12 got higher absolute doses but lower weight-adjusted ones compared to younger children. Why does this matter? It highlights how doctors might unknowingly tailor treatments based on assumptions rather than precise calculations.
Leading the charge are Julia Izsak, a Researcher and Resident in Clinical Pharmacology, and Jenny Kindblom, a Consultant and Professor of Clinical Pharmacology at the University of Gothenburg and Sahlgrenska University Hospital. As Izsak puts it, a notably higher percentage of underweight children and teens stop treatment in the first year compared to those of normal weight. She adds that girls and those over 12 are also more prone to discontinuing early. These findings scream for more research on how dosage impacts the effectiveness and safety of methylphenidate across all weight groups, including underweight, overweight, and obese youth.
But here's where it gets controversial – is this equitable? Are underweight kids getting "too much" medicine, leading to uncomfortable side effects that make them quit? Or are overweight kids getting shortchanged, leaving their ADHD symptoms undertreated? Critics might argue that dosing should always be weight-adjusted from the start to ensure fairness, but what if cultural or medical biases influence decisions, subtly favoring certain groups? For instance, are girls prescribed higher doses because they're seen as needing more control, or is it based on genuine evidence? And don't get me started on age – older kids might handle higher doses, but is that risking long-term health issues?
To give you a quick example, consider two hypothetical kids starting treatment: an underweight 7-year-old girl and an overweight 14-year-old boy. If doses aren't precisely tailored, the girl might feel overly medicated, leading to nausea or loss of appetite, prompting her to stop. The boy, meanwhile, might not get enough relief, wondering why the pills aren't working. This underscores the researchers' call for personalized approaches, considering each child's unique profile when starting and monitoring ADHD treatment. As Izsak notes, huge knowledge gaps exist around medicating children and teens, and more studies could pave the way for smarter, safer strategies across weight statuses.
For more on related topics, check out these intriguing stories:
- Study: Biological underpinnings of autism and ADHD may transcend traditional diagnostic boundaries (https://www.news-medical.net/news/20251112/Study-Biological-underpinnings-of-autism-and-ADHD-may-transcend-traditional-diagnostic-boundaries.aspx)
- Maternal paracetamol use during pregnancy not linked to autism or ADHD in children (https://www.news-medical.net/news/20251110/Maternal-Paracetamol-use-during-pregnancy-not-linked-to-autism-or-ADHD-in-children.aspx)
- Unraveling Tanzania’s Breadbasket paradox in child nutrition (https://www.news-medical.net/news/20251111/Unraveling-Tanzaniae28099s-Breadbasket-paradox-in-child-nutrition.aspx)
What do you think? Does this study make you rethink how ADHD meds are prescribed, or do you see it as overblown? Should weight always dictate dosage, or are there other factors at play, like genetics or lifestyle? Share your thoughts in the comments – agree or disagree, I'd love to hear! Is there a risk we're overlooking in pushing for "equal" dosing, or could this lead to better outcomes for all kids?
Source:
Journal reference:
Izsak, J., et al. (2025). Dosing and Discontinuation of Methylphenidate Medication in Relation to Weight Status in Children and Adolescents. Pediatric Drugs. doi: 10.1007/s40272-025-00728-z. https://link.springer.com/article/10.1007/s40272-025-00728-z
